EATG » Pharma industry

Pharma industry

Merck reinforces commitment to responsible pricing

KENILWORTH, N.J., July 19, 2018 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second…

Novartis drops antibiotics research program

Ceasing work on several experimental antimicrobial projects   CIDRAP News: Novartis drops antibiotic development program “Antibiotic development efforts were dealt a blow when drug maker Novartis AG announced its…

How Big Pharma was captured by the one percent

The industry's price-gouging economic model was engineered by Wall Street and its political enablers—and only Washington can fix it. Read the full article here.

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

-- Details of two-drug HIV trial to be presented July 24 -- GSK hopes to upend conventional three-drug approach -- Doctors may be wary pending further clinical data LONDON, June…

EMA: Guidance for pharmaceutical companies to prepare for UK’s withdrawal from EU

Publication of updated Q+As and practical guidance The European Medicines Agency (EMA) and the European Commission have updated their guidance to help pharmaceutical companies prepare for the United Kingdom’s (UK)…

Hookipa and Gilead enter into a collaboration and license agreement to develop immunotherapies against HIV and hepatitis B

-- Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis B infections -- Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development…

Gilead topples as its hepatitis C drug franchise continues to crumble

Gilead Sciences' hepatitis C downfall accelerated in the first quarter as sales declined by their widest margin in eight periods — prodding shares to topple in after-hours trading Tuesday. The biotech…

GlaxoSmithKline’s next-generation HIV battle against Gilead is already taking a toll on growth

GlaxoSmithKline execs touted their HIV growth drive this week, pointing to next-generation medications Triumeq and Tivicay as the fuel. But both drugs actually fell short of analyst forecasts—and that's thanks…

A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute

In a reversal of fortunes, a federal judge overturned a jury verdict ordering Gilead Sciences (GILD) to pay $2.54 billion to Merck (MRK) for infringing a patent in order to…

ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today (February 8) announced that it has filed patent infringement litigation against…

1 2 3 6